Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. 2009

Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
ACADIA Pharmaceuticals Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121, USA. davis04@gmail.com

BACKGROUND Activation of muscarinic M1 receptors is mediated via interaction of orthosteric agonists with the acetylcholine binding site or via interaction of allosteric agonists with different site(s) on the receptor. The focus of the present study was to determine if M1 receptors activated by allosteric agonists undergo the same regulatory fate as M1 receptors activated by orthosteric agonists. RESULTS The orthosteric agonists carbachol, oxotremorine-M and pilocarpine were compared to the allosteric agonists AC-42, AC-260584, N-desmethylclozapine and xanomeline. All ligands activated M1 receptors and stimulated interaction of the receptors with beta-arrestin-1. All ligands reduced cell surface binding and induced the loss of total receptor binding. Receptor internalization was blocked by treatment with hypertonic sucrose indicating that all ligands induced formation of clathrin coated vesicles. However, internalized receptors recycled to the cell surface following removal of orthosteric, but not allosteric agonists. Whereas all ligands induced loss of cell surface receptor binding, no intracellular vesicles could be observed after treatment with AC-260584 or xanomeline. Brief stimulation of M1 receptors with AC-260584 or xanomeline resulted in persistent activation of M1 receptors, suggesting that continual receptor signaling might impede or delay receptor endocytosis into intracellular vesicles. CONCLUSIONS These results indicate that allosteric agonists differ from orthosteric ligands and among each other in their ability to induce different regulatory pathways. Thus, signaling and regulatory pathways induced by different allosteric ligands are ligand specific.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D043643 Receptor, Muscarinic M1 A specific subtype of muscarinic receptor that has a high affinity for the drug PIRENZEPINE. It is found in the peripheral GANGLIA where it signals a variety of physiological functions such as GASTRIC ACID secretion and BRONCHOCONSTRICTION. This subtype of muscarinic receptor is also found in neuronal tissues including the CEREBRAL CORTEX and HIPPOCAMPUS where it mediates the process of MEMORY and LEARNING. Muscarinic Receptor M1,Muscarinic Receptors M1,Receptors, Muscarinic M1,M1 Receptor, Muscarinic,M1 Receptors, Muscarinic,M1, Muscarinic Receptor,M1, Muscarinic Receptors,Muscarinic M1 Receptor,Muscarinic M1 Receptors,Receptor M1, Muscarinic,Receptors M1, Muscarinic

Related Publications

Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
July 2013, Molecular pharmacology,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
December 2020, ACS omega,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
December 2009, The Journal of pharmacology and experimental therapeutics,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
January 2012, PloS one,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
March 2012, Journal of medicinal chemistry,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
July 2003, Molecular pharmacology,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
December 1993, Molecular pharmacology,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
November 2008, The Journal of pharmacology and experimental therapeutics,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
July 1999, European journal of pharmacology,
Christopher N Davis, and Stefania Risso Bradley, and Hans H Schiffer, and Mikael Friberg, and Kristian Koch, and Bo-Ragnar Tolf, and Douglas W Bonhaus, and Jelveh Lameh
January 1996, Progress in brain research,
Copied contents to your clipboard!